IPH4102

BIOLOGICAL2 trials

Sponsors

Innate Pharma

Conditions

Cutaneous T-Cell LymphomaLymphoma, T-CellLymphoma, T-Cell, CutaneousMycosis Fungoides/Sezary Syndrome

Phase 1

Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

CompletedNCT02593045

Innate PharmaCutaneous T-Cell Lymphoma

Start: 2015-10-31End: 2020-04-30Updated: 2021-01-20

Phase 2

IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

CompletedNCT03902184

Innate PharmaLymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome

Start: 2019-05-22End: 2026-01-08Updated: 2026-04-29

Related Papers

Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial.

Journal of Clinical Oncology2025-05-282 citations

Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Long-term follow-up and translational data from the TELLOMAK phase 2 trial.

Journal of Clinical Oncology2025-05-28

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Blood2024-11-053 citations

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood2024-11-052 citations

Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial.

Journal of Clinical Oncology2024-06-018 citations

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Blood2023-11-024 citations

LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF): EFFICACY RESULTS ACCORDING TO UPDATED LYMPH NODE (LN) CLASSIFICATION IN THE TELLOMAK STUDY

Hematological Oncology2023-06-012 citations

KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA

Hematological Oncology2023-06-011 citations

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Blood2022-11-155 citations

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.

2019-06-25116 citations

KIR3DL2 IS EXPRESSED IN PERIPHERAL T‐CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET

Hematological Oncology2019-06-011 citations

MEMBRANE EXPRESSION OF NK RECEPTOR KIR3DL2 CONTRIBUTES TO DELINEATE THE ACUTE‐TYPE AND IS A THERAPEUTIC TARGET IN ADULT T‐CELL LEUKEMIA/LYMPHOMA

Hematological Oncology2019-06-01

Phase I Study of IPH4102, Anti‐KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T‐Cell Lymphomas (CTCL): Dose‐escalation Safety, Biomarker and Clinical Activity Results

Hematological Oncology2017-06-0110 citations

First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results

Blood2016-12-028 citations

First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas.

Journal of Clinical Oncology2016-05-20